METHODS: We retrospectively analyzed 181 patients with LAGC who underwent curative resection after neoadjuvant chemotherapy in a prospective study (NCT01516944). We divided these patients into tumour regression grade(TRG) 3 and non-TRG3 groups based on tumor response (AJCC/CAP guidelines). The SII and PNI were assessed and confirmed the cut-off values before treatment. The SII-PNI values varied from 0 to 2, with 2 being the high SII (≥ 471.5) as well as low PNI (≤ 48.6), a high SII or low PNI is represented by a 1 and neither is represented by a 0, respectively.
RESULTS: 51 and 130 samples had TRG3 and non-TRG3 tumor responses respectively. Patients with TRG3 had substantially higher SII-PNI scores than those without TRG3 (p < 0.0001). Patients with greater SII-PNI scores had a poorer prognosis (p < 0.0001). The SII-PNI score was found to be an independent predictor of both overall survival (HR = 4.982, 95%CI: 1.890-10.234, p = 0.001) and disease-free survival (HR = 4.763, 95%CI: 1.994-13.903, p = 0.001) in a multivariate analysis.
CONCLUSIONS: The clinical potential and accuracy of low-cost stratification based on SII-PNI score in forecasting tumor response and prognosis in LAGC is satisfactory.
方法:我们在一项前瞻性研究(NCT01516944)中回顾性分析了181例LAGC患者在新辅助化疗后接受根治性切除术。我们根据肿瘤反应(AJCC/CAP指南)将这些患者分为肿瘤消退等级(TRG)3和非TRG3组。在治疗前评估SII和PNI并确认截止值。SII-PNI值在0到2之间变化,其中2为高SII(≥471.5)和低PNI(≤48.6),高SII或低PNI分别由1表示,并且两者都不由0表示。
结果:51和130个样品分别具有TRG3和非TRG3肿瘤反应。TRG3患者的SII-PNI评分明显高于无TRG3患者(p<0.0001)。SII-PNI评分较高的患者预后较差(p<0.0001)。在多变量分析中发现SII-PNI评分是总生存期(HR=4.982,95CI:1.890-10.234,p=0.001)和无病生存期(HR=4.763,95CI:1.994-13.903,p=0.001)的独立预测因子。
结论:基于SII-PNI评分的低成本分层在预测LAGC肿瘤反应和预后方面的临床潜力和准确性令人满意。